BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 8396086)

  • 1. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections.
    Hoepelman AI; Sips AP; van Helmond JL; van Barneveld PW; Neve AJ; Zwinkels M; Rozenberg-Arska M; Verhoef J
    J Antimicrob Chemother; 1993 Jun; 31 Suppl E():147-52. PubMed ID: 8396086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome.
    Hoepelman IM; Möllers MJ; van Schie MH; Greefhorst AP; Schlösser NJ; Sinninghe Damsté EJ; van de Moosdijk CN; Dalinghaus WH; Eland ME; Mol SJ; Rozenberg-Arska M
    Int J Antimicrob Agents; 1997 Jan; 9(3):141-6. PubMed ID: 9552709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study.
    Gris P
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():93-101. PubMed ID: 8818850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.
    Dere WH; Farlow D; Therasse DG; Jacobson KD; Guerra FJ
    Clin Ther; 1992; 14(2):166-77. PubMed ID: 1611641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections.
    Zachariah J
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():103-13. PubMed ID: 8818851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zeckel ML; Jacobson KD; Guerra FJ; Therasse DG; Farlow D
    Clin Ther; 1992; 14(2):214-29. PubMed ID: 1611645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children.
    Schaad UB
    J Antimicrob Chemother; 1993 Jun; 31 Suppl E():81-8. PubMed ID: 8396101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions.
    Kaiser L; Lew D; Hirschel B; Auckenthaler R; Morabia A; Heald A; Benedict P; Terrier F; Wunderli W; Matter L; Germann D; Voegeli J; Stalder H
    Lancet; 1996 Jun; 347(9014):1507-10. PubMed ID: 8684101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. European Azithromycin Study Group.
    Daniel R
    J Int Med Res; 1991; 19(5):373-83. PubMed ID: 1660824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections.
    Balmes P; Clerc G; Dupont B; Labram C; Pariente R; Poirier R
    Eur J Clin Microbiol Infect Dis; 1991 May; 10(5):437-9. PubMed ID: 1651860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children.
    Daniel RR
    J Antimicrob Chemother; 1993 Jun; 31 Suppl E():65-71. PubMed ID: 8396099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis.
    Mertens JC; van Barneveld PW; Asin HR; Ligtvoet E; Visser MR; Branger T; Hoepelman AI
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1456-9. PubMed ID: 1324645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
    Geddes AM
    Drugs; 1991; 42 Suppl 3():34-40. PubMed ID: 1726206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
    Lode H
    Dtsch Med Wochenschr; 1999 Dec; 124(48):1459-61. PubMed ID: 10615328
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults.
    Clement PA; de Gandt JB
    J Int Med Res; 1998; 26(2):66-75. PubMed ID: 9602984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amoxycillin/clavulanate in acute purulent exacerbations of chronic bronchitis.
    Maesen FP; Davies BI; Baur C
    J Antimicrob Chemother; 1987 Mar; 19(3):373-83. PubMed ID: 3494724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of cefprozil and amoxycillin/clavulanate in the treatment of acute otitis media in children.
    Gehanno P; Berche P; Boucot I; Lambert-Zechovsky N; Bingen E; Gres JJ; Rollin C
    J Antimicrob Chemother; 1994 Jun; 33(6):1209-18. PubMed ID: 7928814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group.
    Biebuyck XA
    J Int Med Res; 1996; 24(5):407-18. PubMed ID: 8895044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of nasopharyngeal culture in antibiotic prescription for patients with common cold or acute sinusitis.
    Kaiser L; Morabia A; Stalder H; Ricchetti A; Auckenthaler R; Terrier F; Hirschel B; Khaw N; Lacroix JS; Lew D
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):445-51. PubMed ID: 11561799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.
    Cazzola M; Vinciguerra A; Beghi GF; Paizis G; Giura R; Madonini V; Fiorentini F; Consigli GF; Tonna M; Casalini A
    J Chemother; 1995 Oct; 7(5):432-41. PubMed ID: 8596127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.